Biodesix vs Ridgetech
Ridgetech reported revenue of $132 million in fiscal 2026, 1.5 times Biodesix's $88 million in fiscal 2025. Biodesix's revenue grew 24.1% in its latest year, and Ridgetech's grew 10.2%. Biodesix had an operating margin of -31.5%, against -1.4% at Ridgetech. Free cash flow was −$24 million at Biodesix and −$1 million at Ridgetech. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Biodesix | Ridgetech | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $88M | $132M |
| Revenue growth | 24.1% | 10.2% |
| Revenue growth a year, last 5 years | 14.2% | −0.1% |
| Gross margin | — | 3.6% |
| Operating margin | −31.5% | −1.4% |
| Net margin | −39.9% | −0.9% |
| Free cash flow | −$24M | −$1M |
| Free cash flow margin | −26.6% | −1.1% |
| Return on capital | −69.7% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 16.7% | 96.6% |
| Last close | $8.30 | $1.02 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $3.1 million, sold $104,401 | bought $161,242, sold $115,597 |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BiodesixRidgetech
Operating margin
Percent of revenue
BiodesixRidgetech
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BiodesixRidgetech
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Biodesix and Ridgetech pages.